睾酮治疗不增加主动监测前列腺癌患者的疾病进展风险
本研究回顾了3324例接受主动监测的1-2级组前列腺癌患者,其中79例同时接受睾酮治疗。多因素分析显示,睾酮治疗未显著影响疾病进展风险(HR 0.99;95%CI:0.67-1.48;P > .9)及进展至根治性治疗的风险(HR 0.94;95%CI:0.64-1.38;P = .8)。结论认为睾酮治疗可用于主动监测患者,但需密切监测,仍需更大样本更成熟队列验证肿瘤安全性。
要点
- 睾酮治疗未显著增加主动监测前列腺癌患者的活检分级进展风险。
- 睾酮治疗也未显著影响进展至根治性治疗的风险。
- 接受睾酮治疗的患者需密切监测,证据仍需更大样本验证。
核心结论
- 在主动监测的前列腺癌患者中,睾酮治疗未与疾病进展风险增加相关。
研究设计与样本
- 回顾性队列研究,纳入3324例接受主动监测的1-2级组前列腺癌患者,其中79例同时接受睾酮治疗。
主要发现
- 1256例(38%)患者出现活检分级进展。
- 多因素分析显示睾酮治疗对疾病进展风险无显著影响(HR 0.99;95%CI:0.67-1.48;P > .9)。
- 睾酮治疗对进展至根治性治疗的风险也无显著影响(HR 0.94;95%CI:0.64-1.38;P = .8)。
- 调整后生存曲线未显示事件率有临床意义的差异。
关键数值与推荐
- 主动监测方案包括每6个月实验室检查和体格检查,每18个月MRI,每36个月活检。
- 睾酮治疗患者起始后2-4周及剂量稳定后每6个月检测总睾酮和PSA。
- 主要结局为活检分级组升高时间,次要结局为进展至根治性治疗。
临床怎么用
- 对于主动监测的前列腺癌患者,睾酮治疗并非绝对禁忌,但应密切监测。
- 需与患者充分沟通,个体化决策,并进一步研究确认肿瘤安全性。
局限性
- 睾酮治疗组样本量较小(79例)。
- 为回顾性研究,可能存在选择偏倚。
- 需要更大样本和更成熟队列验证肿瘤安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Testosterone therapy (TTH) in men with prostate cancer (PC) remains controversial, with limited data on cancer-specific outcomes for patients on TTH available, particularly for those on active surveillance (AS). This study aimed to assess the safety of TTh in men on AS for PC. MATERIALS AND METHODS: The records of patients with grade group (GG) 1 and 2 PC on AS were reviewed, including a subset who were concurrently treated with TTH. Institutional protocols for AS consisted of laboratory work and examination every 6 months, MRI every 18 months, and biopsy every 36 months. Men on TTH had total testosterone, and PSA laboratory test results drawn within 2 to 4 weeks of TTH initiation and every 6 months when stable on dosing. The primary outcome was time to progression, defined as a rise in GG on biopsy. A secondary outcome used an alternative definition of progression to definitive treatment. RESULTS: The study included 3324 AS patients, with 79 on TTH. In total, 1256 (38%) patients had progression on biopsy. On multivariable analysis, TTH did not significantly affect the risk of disease progression (HR 0.99; 95% CI: 0.67-1.48; P > .9), with adjusted survival curves failing to demonstrate clinically meaningful differences in event rates. Similarly, TTH did not affect progression to definitive treatment (HR 0.94; 95% CI: 0.64-1.38; P = .8). CONCLUSIONS: Although TTh can be used in patients on AS, careful monitoring is indicated and further research necessary to confirm oncologic safety with larger and more mature cohorts.
引用
- Flores JM, Kim D, Yu R, et al. Testosterone Therapy in Men on Active Surveillance for Prostate Cancer Is Not Associated With Increased Risk of Disease Progression. J Urol. 2026. PMID: 42636428. doi:10.1097/JU.0000000000005276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。